IQVIA (NYSE:IQV) Sets New 12-Month Low Following Analyst Downgrade

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) shares reached a new 52-week low on Wednesday after Citigroup lowered their price target on the stock from $225.00 to $210.00. Citigroup currently has a neutral rating on the stock. IQVIA traded as low as $179.28 and last traded at $183.75, with a volume of 1649439 shares changing hands. The stock had previously closed at $184.85.

IQV has been the subject of several other research reports. Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. JPMorgan Chase & Co. lowered their target price on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. Finally, Leerink Partners restated an "outperform" rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.

Institutional Investors Weigh In On IQVIA

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Capital Performance Advisors LLP acquired a new position in IQVIA during the third quarter worth $27,000. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth about $33,000. Avior Wealth Management LLC lifted its position in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new position in IQVIA during the 4th quarter valued at about $39,000. Finally, Lee Danner & Bass Inc. bought a new stake in IQVIA during the 4th quarter worth approximately $44,000. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 0.1 %

The stock has a market capitalization of $32.74 billion, a PE ratio of 24.74, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a 50 day moving average price of $198.24 and a 200 day moving average price of $213.66.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.